APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Pulmonary Drugs Industry Research Report 2026

22 December 2025141 pages

Choose your research edition.

Industry ResearchPulmonary Drugs Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Drugs Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Pulmonary Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Drugs Market Outlook and Growth Opportunities 2026211 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Drugs Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Pulmonary Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Pulmonary Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Pulmonary Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Pulmonary Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Pulmonary Drugs include Teva Pharmaceutical Industries Ltd., Sanofi SA, Novartis AG, GlaxoSmithKline Plc., Glenmark Pharmaceuticals Ltd., AbbVie Inc., AstraZeneca Plc., Zambon Company S.p.A and Wellona Pharma, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Pulmonary Drugs market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Pulmonary Drugs.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Pulmonary Drugs Market by Company

Teva Pharmaceutical Industries Ltd.

Sanofi SA

Novartis AG

GlaxoSmithKline Plc.

Glenmark Pharmaceuticals Ltd.

AbbVie Inc.

AstraZeneca Plc.

Zambon Company S.p.A

Wellona Pharma

Vertex Pharmaceuticals Inc.

Sumitomo Pharma Co. Ltd.

Merck Sharp & Dohme Limited

Medisol Lifescience Pvt. Ltd.

Meda Pharmaceuticals

Mallinckrodt Pharmaceuticals Plc.

Lupin Ltd.

Grifols, S.A.

F. Hoffmann La Roche Ltd.

Circassia Pharmaceuticals Plc.

Cipla Ltd.

Cheisi Farmaceutici S.p.A

Celon Pharma SA

Boehringer Ingelheim

Aurobindo Pharma Ltd.

Alaxia SAS

Aerogen Pharma Ltd.

Abbott Laboratories

Pulmonary Drugs Segment by Type

Antihistamines

Inhaled Corticosteroids

Vasodilators

Long Acting Beta-2 Agonists

Others

Pulmonary Drugs Segment by Application

Asthma & COPD

Cystic Fibrosis

Pulmonary Arterial Hypertension

Allergic Rhinitis

Others

Pulmonary Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Pulmonary Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Pulmonary Drugs Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Pulmonary Drugs Revenue Market Share by Type (2021-2026) Table 7. Global Pulmonary Drugs Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Pulmonary Drugs Revenue Market Share by Type (2027-2032) Table 9. Global Pulmonary Drugs Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Pulmonary Drugs Revenue Market Share by Application (2021-2026) Table 11. Global Pulmonary Drugs Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Pulmonary Drugs Revenue Market Share by Application (2027-2032) Table 13. Global Pulmonary Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Pulmonary Drugs Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Pulmonary Drugs Market Share by Region (2021-2026) Table 16. Global Pulmonary Drugs Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Pulmonary Drugs Market Share by Region (2027-2032) Table 18. Pulmonary Drugs Industry Trends Table 19. Pulmonary Drugs Industry Drivers Table 20. Pulmonary Drugs Industry Opportunities and Challenges Table 21. Pulmonary Drugs Market Restraints Table 22. Global Top Pulmonary Drugs Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Pulmonary Drugs Revenue Market Share by Players (2021-2026) Table 24. Global Pulmonary Drugs Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Pulmonary Drugs, Headquarters and Area Served Table 26. Global Pulmonary Drugs Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Pulmonary Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Pulmonary Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Pulmonary Drugs Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Pulmonary Drugs Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Pulmonary Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Pulmonary Drugs Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Pulmonary Drugs Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Pulmonary Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Pulmonary Drugs Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Pulmonary Drugs Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Pulmonary Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Pulmonary Drugs Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Pulmonary Drugs Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Pulmonary Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Pulmonary Drugs Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Pulmonary Drugs Market Size by Country (2027-2032) & (US$ Million) Table 45. Teva Pharmaceutical Industries Ltd. Company Information Table 46. Teva Pharmaceutical Industries Ltd. Business Overview Table 47. Teva Pharmaceutical Industries Ltd. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 48. Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Product Portfolio Table 49. Teva Pharmaceutical Industries Ltd. Recent Developments Table 50. Sanofi SA Company Information Table 51. Sanofi SA Business Overview Table 52. Sanofi SA Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 53. Sanofi SA Pulmonary Drugs Product Portfolio Table 54. Sanofi SA Recent Developments Table 55. Novartis AG Company Information Table 56. Novartis AG Business Overview Table 57. Novartis AG Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 58. Novartis AG Pulmonary Drugs Product Portfolio Table 59. Novartis AG Recent Developments Table 60. GlaxoSmithKline Plc. Company Information Table 61. GlaxoSmithKline Plc. Business Overview Table 62. GlaxoSmithKline Plc. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 63. GlaxoSmithKline Plc. Pulmonary Drugs Product Portfolio Table 64. GlaxoSmithKline Plc. Recent Developments Table 65. Glenmark Pharmaceuticals Ltd. Company Information Table 66. Glenmark Pharmaceuticals Ltd. Business Overview Table 67. Glenmark Pharmaceuticals Ltd. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 68. Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Product Portfolio Table 69. Glenmark Pharmaceuticals Ltd. Recent Developments Table 70. AbbVie Inc. Company Information Table 71. AbbVie Inc. Business Overview Table 72. AbbVie Inc. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 73. AbbVie Inc. Pulmonary Drugs Product Portfolio Table 74. AbbVie Inc. Recent Developments Table 75. AstraZeneca Plc. Company Information Table 76. AstraZeneca Plc. Business Overview Table 77. AstraZeneca Plc. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 78. AstraZeneca Plc. Pulmonary Drugs Product Portfolio Table 79. AstraZeneca Plc. Recent Developments Table 80. Zambon Company S.p.A Company Information Table 81. Zambon Company S.p.A Business Overview Table 82. Zambon Company S.p.A Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 83. Zambon Company S.p.A Pulmonary Drugs Product Portfolio Table 84. Zambon Company S.p.A Recent Developments Table 85. Wellona Pharma Company Information Table 86. Wellona Pharma Business Overview Table 87. Wellona Pharma Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 88. Wellona Pharma Pulmonary Drugs Product Portfolio Table 89. Wellona Pharma Recent Developments Table 90. Vertex Pharmaceuticals Inc. Company Information Table 91. Vertex Pharmaceuticals Inc. Business Overview Table 92. Vertex Pharmaceuticals Inc. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 93. Vertex Pharmaceuticals Inc. Pulmonary Drugs Product Portfolio Table 94. Vertex Pharmaceuticals Inc. Recent Developments Table 95. Sumitomo Pharma Co. Ltd. Company Information Table 96. Sumitomo Pharma Co. Ltd. Business Overview Table 97. Sumitomo Pharma Co. Ltd. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 98. Sumitomo Pharma Co. Ltd. Pulmonary Drugs Product Portfolio Table 99. Sumitomo Pharma Co. Ltd. Recent Developments Table 100. Merck Sharp & Dohme Limited Company Information Table 101. Merck Sharp & Dohme Limited Business Overview Table 102. Merck Sharp & Dohme Limited Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 103. Merck Sharp & Dohme Limited Pulmonary Drugs Product Portfolio Table 104. Merck Sharp & Dohme Limited Recent Developments Table 105. Medisol Lifescience Pvt. Ltd. Company Information Table 106. Medisol Lifescience Pvt. Ltd. Business Overview Table 107. Medisol Lifescience Pvt. Ltd. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 108. Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Product Portfolio Table 109. Medisol Lifescience Pvt. Ltd. Recent Developments Table 110. Meda Pharmaceuticals Company Information Table 111. Meda Pharmaceuticals Business Overview Table 112. Meda Pharmaceuticals Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 113. Meda Pharmaceuticals Pulmonary Drugs Product Portfolio Table 114. Meda Pharmaceuticals Recent Developments Table 115. Mallinckrodt Pharmaceuticals Plc. Company Information Table 116. Mallinckrodt Pharmaceuticals Plc. Business Overview Table 117. Mallinckrodt Pharmaceuticals Plc. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 118. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio Table 119. Mallinckrodt Pharmaceuticals Plc. Recent Developments Table 120. Lupin Ltd. Company Information Table 121. Lupin Ltd. Business Overview Table 122. Lupin Ltd. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 123. Lupin Ltd. Pulmonary Drugs Product Portfolio Table 124. Lupin Ltd. Recent Developments Table 125. Grifols, S.A. Company Information Table 126. Grifols, S.A. Business Overview Table 127. Grifols, S.A. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 128. Grifols, S.A. Pulmonary Drugs Product Portfolio Table 129. Grifols, S.A. Recent Developments Table 130. F. Hoffmann La Roche Ltd. Company Information Table 131. F. Hoffmann La Roche Ltd. Business Overview Table 132. F. Hoffmann La Roche Ltd. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 133. F. Hoffmann La Roche Ltd. Pulmonary Drugs Product Portfolio Table 134. F. Hoffmann La Roche Ltd. Recent Developments Table 135. Circassia Pharmaceuticals Plc. Company Information Table 136. Circassia Pharmaceuticals Plc. Business Overview Table 137. Circassia Pharmaceuticals Plc. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 138. Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio Table 139. Circassia Pharmaceuticals Plc. Recent Developments Table 140. Cipla Ltd. Company Information Table 141. Cipla Ltd. Business Overview Table 142. Cipla Ltd. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 143. Cipla Ltd. Pulmonary Drugs Product Portfolio Table 144. Cipla Ltd. Recent Developments Table 145. Cheisi Farmaceutici S.p.A Company Information Table 146. Cheisi Farmaceutici S.p.A Business Overview Table 147. Cheisi Farmaceutici S.p.A Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 148. Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Portfolio Table 149. Cheisi Farmaceutici S.p.A Recent Developments Table 150. Celon Pharma SA Company Information Table 151. Celon Pharma SA Business Overview Table 152. Celon Pharma SA Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 153. Celon Pharma SA Pulmonary Drugs Product Portfolio Table 154. Celon Pharma SA Recent Developments Table 155. Boehringer Ingelheim Company Information Table 156. Boehringer Ingelheim Business Overview Table 157. Boehringer Ingelheim Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 158. Boehringer Ingelheim Pulmonary Drugs Product Portfolio Table 159. Boehringer Ingelheim Recent Developments Table 160. Aurobindo Pharma Ltd. Company Information Table 161. Aurobindo Pharma Ltd. Business Overview Table 162. Aurobindo Pharma Ltd. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 163. Aurobindo Pharma Ltd. Pulmonary Drugs Product Portfolio Table 164. Aurobindo Pharma Ltd. Recent Developments Table 165. Alaxia SAS Company Information Table 166. Alaxia SAS Business Overview Table 167. Alaxia SAS Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 168. Alaxia SAS Pulmonary Drugs Product Portfolio Table 169. Alaxia SAS Recent Developments Table 170. Aerogen Pharma Ltd. Company Information Table 171. Aerogen Pharma Ltd. Business Overview Table 172. Aerogen Pharma Ltd. Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 173. Aerogen Pharma Ltd. Pulmonary Drugs Product Portfolio Table 174. Aerogen Pharma Ltd. Recent Developments Table 175. Abbott Laboratories Company Information Table 176. Abbott Laboratories Business Overview Table 177. Abbott Laboratories Revenue in Pulmonary Drugs Business (2021-2026) & (US$ Million) Table 178. Abbott Laboratories Pulmonary Drugs Product Portfolio Table 179. Abbott Laboratories Recent Developments Table 180. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Pulmonary Drugs Product Image Figure 5. Global Pulmonary Drugs Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Pulmonary Drugs Market Share by Type: 2025 VS 2032 Figure 7. Antihistamines Product Figure 8. Inhaled Corticosteroids Product Figure 9. Vasodilators Product Figure 10. Long Acting Beta-2 Agonists Product Figure 11. Others Product Figure 12. Global Pulmonary Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Pulmonary Drugs Market Share by Application: 2025 VS 2032 Figure 14. Asthma & COPD Product Figure 15. Cystic Fibrosis Product Figure 16. Pulmonary Arterial Hypertension Product Figure 17. Allergic Rhinitis Product Figure 18. Others Product Figure 19. Global Pulmonary Drugs Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 20. Global Pulmonary Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 21. Global Pulmonary Drugs Market Share by Region: 2025 VS 2032 Figure 22. Global Pulmonary Drugs Market Share by Players in 2025 Figure 23. Global Pulmonary Drugs Manufacturers Established Date Figure 24. Global Top 5 and 10 Pulmonary Drugs Players Market Share by Revenue in 2025 Figure 25. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. North America Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Pulmonary Drugs Market Share by Country (2021-2032) Figure 28. United States Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Canada Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. Mexico Pulmonary Drugs Market Share by Country (2021-2032) Figure 31. Europe Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Pulmonary Drugs Market Share by Country (2021-2032) Figure 33. Germany Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. France Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. U.K. Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Italy Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Spain Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Russia Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Netherlands Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. Nordic Countries Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. Asia-Pacific Pulmonary Drugs Market Share by Country (2021-2032) Figure 43. China Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. Japan Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. South Korea Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. India Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. India Pulmonary Drugs Market Share by Country (2021-2032) Figure 48. Australia Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. China Taiwan Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Southeast Asia Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. South America Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. South America Pulmonary Drugs Market Share by Country (2021-2032) Figure 53. Brazil Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Argentina Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 55. Chile Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 56. Colombia Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 57. Peru Pulmonary Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 58. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 59. Sanofi SA Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 60. Novartis AG Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 61. GlaxoSmithKline Plc. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 62. Glenmark Pharmaceuticals Ltd. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 63. AbbVie Inc. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 64. AstraZeneca Plc. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 65. Zambon Company S.p.A Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 66. Wellona Pharma Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 67. Vertex Pharmaceuticals Inc. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 68. Sumitomo Pharma Co. Ltd. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 69. Merck Sharp & Dohme Limited Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 70. Medisol Lifescience Pvt. Ltd. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 71. Meda Pharmaceuticals Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 72. Mallinckrodt Pharmaceuticals Plc. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 73. Lupin Ltd. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 74. Grifols, S.A. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 75. F. Hoffmann La Roche Ltd. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 76. Circassia Pharmaceuticals Plc. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 77. Cipla Ltd. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 78. Cheisi Farmaceutici S.p.A Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 79. Celon Pharma SA Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 80. Boehringer Ingelheim Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 81. Aurobindo Pharma Ltd. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 82. Alaxia SAS Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 83. Aerogen Pharma Ltd. Revenue Growth Rate in Pulmonary Drugs Business (2021-2026) Figure 84. Abbott Laboratories Revenue Growth Rate in Pulmonary Drugs Business (2021-2026)

Scope & coverage.

Types
  • Antihistamines
  • Inhaled Corticosteroids
  • Vasodilators
  • Long Acting Beta-2 Agonists
  • Others
Applications
  • Asthma & COPD
  • Cystic Fibrosis
  • Pulmonary Arterial Hypertension
  • Allergic Rhinitis
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis AG
  • GlaxoSmithKline Plc.
  • Glenmark Pharmaceuticals Ltd.
  • AbbVie Inc.
  • AstraZeneca Plc.
  • Zambon Company S.p.A
  • Wellona Pharma
  • Vertex Pharmaceuticals Inc.
  • Sumitomo Pharma Co. Ltd.
  • Merck Sharp & Dohme Limited
  • Medisol Lifescience Pvt. Ltd.
  • Meda Pharmaceuticals
  • Mallinckrodt Pharmaceuticals Plc.
  • Lupin Ltd.
  • Grifols, S.A.
  • F. Hoffmann La Roche Ltd.
  • Circassia Pharmaceuticals Plc.
  • Cipla Ltd.
  • Cheisi Farmaceutici S.p.A
  • Celon Pharma SA
  • Boehringer Ingelheim
  • Aurobindo Pharma Ltd.
  • Alaxia SAS
  • Aerogen Pharma Ltd.
  • Abbott Laboratories

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Pulmonary Drugs by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Antihistamines
  5. 2.2.3 Inhaled Corticosteroids
  6. 2.2.4 Vasodilators
  7. 2.2.5 Long Acting Beta-2 Agonists
  8. 2.2.6 Others
  9. 2.3 Pulmonary Drugs by Application
  10. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  11. 2.3.2 Asthma & COPD
  12. 2.3.3 Cystic Fibrosis
  13. 2.3.4 Pulmonary Arterial Hypertension
  14. 2.3.5 Allergic Rhinitis
  15. 2.3.6 Others
  16. 2.4 Assumptions and Limitations
3 Pulmonary Drugs Breakdown Data by Type
  1. 3.1 Global Pulmonary Drugs Historic Market Size by Type (2021-2026)
  2. 3.2 Global Pulmonary Drugs Forecasted Market Size by Type (2027-2032)
4 Pulmonary Drugs Breakdown Data by Application
  1. 4.1 Global Pulmonary Drugs Historic Market Size by Application (2021-2026)
  2. 4.2 Global Pulmonary Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Pulmonary Drugs Market Perspective (2021-2032)
  2. 5.2 Global Pulmonary Drugs Growth Trends by Region
  3. 5.2.1 Global Pulmonary Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Pulmonary Drugs Historic Market Size by Region (2021-2026)
  5. 5.2.3 Pulmonary Drugs Forecasted Market Size by Region (2027-2032)
  6. 5.3 Pulmonary Drugs Market Dynamics
  7. 5.3.1 Pulmonary Drugs Industry Trends
  8. 5.3.2 Pulmonary Drugs Market Drivers
  9. 5.3.3 Pulmonary Drugs Market Challenges
  10. 5.3.4 Pulmonary Drugs Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Pulmonary Drugs Players by Revenue
  2. 6.1.1 Global Top Pulmonary Drugs Players by Revenue (2021-2026)
  3. 6.1.2 Global Pulmonary Drugs Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Pulmonary Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Pulmonary Drugs Head Office and Area Served
  6. 6.4 Global Pulmonary Drugs Players, Product Type & Application
  7. 6.5 Global Pulmonary Drugs Manufacturers Established Date
  8. 6.6 Global Pulmonary Drugs Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Pulmonary Drugs Market Size (2021-2032)
  2. 7.2 North America Pulmonary Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Pulmonary Drugs Market Size by Country (2021-2026)
  4. 7.4 North America Pulmonary Drugs Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Pulmonary Drugs Market Size (2021-2032)
  2. 8.2 Europe Pulmonary Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Pulmonary Drugs Market Size by Country (2021-2026)
  4. 8.4 Europe Pulmonary Drugs Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Pulmonary Drugs Market Size (2021-2032)
  2. 9.2 Asia-Pacific Pulmonary Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Pulmonary Drugs Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Pulmonary Drugs Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Pulmonary Drugs Market Size (2021-2032)
  2. 10.2 South America Pulmonary Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Pulmonary Drugs Market Size by Country (2021-2026)
  4. 10.4 South America Pulmonary Drugs Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Pulmonary Drugs Market Size (2021-2032)
  2. 11.2 Middle East & Africa Pulmonary Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Pulmonary Drugs Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Pulmonary Drugs Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Teva Pharmaceutical Industries Ltd.
  2. 12.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 12.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 12.1.3 Teva Pharmaceutical Industries Ltd. Revenue in Pulmonary Drugs Business (2021-2026)
  5. 12.1.4 Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Product Portfolio
  6. 12.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 12.2 Sanofi SA
  8. 12.2.1 Sanofi SA Company Information
  9. 12.2.2 Sanofi SA Business Overview
  10. 12.2.3 Sanofi SA Revenue in Pulmonary Drugs Business (2021-2026)
  11. 12.2.4 Sanofi SA Pulmonary Drugs Product Portfolio
  12. 12.2.5 Sanofi SA Recent Developments
  13. 12.3 Novartis AG
  14. 12.3.1 Novartis AG Company Information
  15. 12.3.2 Novartis AG Business Overview
  16. 12.3.3 Novartis AG Revenue in Pulmonary Drugs Business (2021-2026)
  17. 12.3.4 Novartis AG Pulmonary Drugs Product Portfolio
  18. 12.3.5 Novartis AG Recent Developments
  19. 12.4 GlaxoSmithKline Plc.
  20. 12.4.1 GlaxoSmithKline Plc. Company Information
  21. 12.4.2 GlaxoSmithKline Plc. Business Overview
  22. 12.4.3 GlaxoSmithKline Plc. Revenue in Pulmonary Drugs Business (2021-2026)
  23. 12.4.4 GlaxoSmithKline Plc. Pulmonary Drugs Product Portfolio
  24. 12.4.5 GlaxoSmithKline Plc. Recent Developments
  25. 12.5 Glenmark Pharmaceuticals Ltd.
  26. 12.5.1 Glenmark Pharmaceuticals Ltd. Company Information
  27. 12.5.2 Glenmark Pharmaceuticals Ltd. Business Overview
  28. 12.5.3 Glenmark Pharmaceuticals Ltd. Revenue in Pulmonary Drugs Business (2021-2026)
  29. 12.5.4 Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Product Portfolio
  30. 12.5.5 Glenmark Pharmaceuticals Ltd. Recent Developments
  31. 12.6 AbbVie Inc.
  32. 12.6.1 AbbVie Inc. Company Information
  33. 12.6.2 AbbVie Inc. Business Overview
  34. 12.6.3 AbbVie Inc. Revenue in Pulmonary Drugs Business (2021-2026)
  35. 12.6.4 AbbVie Inc. Pulmonary Drugs Product Portfolio
  36. 12.6.5 AbbVie Inc. Recent Developments
  37. 12.7 AstraZeneca Plc.
  38. 12.7.1 AstraZeneca Plc. Company Information
  39. 12.7.2 AstraZeneca Plc. Business Overview
  40. 12.7.3 AstraZeneca Plc. Revenue in Pulmonary Drugs Business (2021-2026)
  41. 12.7.4 AstraZeneca Plc. Pulmonary Drugs Product Portfolio
  42. 12.7.5 AstraZeneca Plc. Recent Developments
  43. 12.8 Zambon Company S.p.A
  44. 12.8.1 Zambon Company S.p.A Company Information
  45. 12.8.2 Zambon Company S.p.A Business Overview
  46. 12.8.3 Zambon Company S.p.A Revenue in Pulmonary Drugs Business (2021-2026)
  47. 12.8.4 Zambon Company S.p.A Pulmonary Drugs Product Portfolio
  48. 12.8.5 Zambon Company S.p.A Recent Developments
  49. 12.9 Wellona Pharma
  50. 12.9.1 Wellona Pharma Company Information
  51. 12.9.2 Wellona Pharma Business Overview
  52. 12.9.3 Wellona Pharma Revenue in Pulmonary Drugs Business (2021-2026)
  53. 12.9.4 Wellona Pharma Pulmonary Drugs Product Portfolio
  54. 12.9.5 Wellona Pharma Recent Developments
  55. 12.10 Vertex Pharmaceuticals Inc.
  56. 12.10.1 Vertex Pharmaceuticals Inc. Company Information
  57. 12.10.2 Vertex Pharmaceuticals Inc. Business Overview
  58. 12.10.3 Vertex Pharmaceuticals Inc. Revenue in Pulmonary Drugs Business (2021-2026)
  59. 12.10.4 Vertex Pharmaceuticals Inc. Pulmonary Drugs Product Portfolio
  60. 12.10.5 Vertex Pharmaceuticals Inc. Recent Developments
  61. 12.11 Sumitomo Pharma Co. Ltd.
  62. 12.11.1 Sumitomo Pharma Co. Ltd. Company Information
  63. 12.11.2 Sumitomo Pharma Co. Ltd. Business Overview
  64. 12.11.3 Sumitomo Pharma Co. Ltd. Revenue in Pulmonary Drugs Business (2021-2026)
  65. 12.11.4 Sumitomo Pharma Co. Ltd. Pulmonary Drugs Product Portfolio
  66. 12.11.5 Sumitomo Pharma Co. Ltd. Recent Developments
  67. 12.12 Merck Sharp & Dohme Limited
  68. 12.12.1 Merck Sharp & Dohme Limited Company Information
  69. 12.12.2 Merck Sharp & Dohme Limited Business Overview
  70. 12.12.3 Merck Sharp & Dohme Limited Revenue in Pulmonary Drugs Business (2021-2026)
  71. 12.12.4 Merck Sharp & Dohme Limited Pulmonary Drugs Product Portfolio
  72. 12.12.5 Merck Sharp & Dohme Limited Recent Developments
  73. 12.13 Medisol Lifescience Pvt. Ltd.
  74. 12.13.1 Medisol Lifescience Pvt. Ltd. Company Information
  75. 12.13.2 Medisol Lifescience Pvt. Ltd. Business Overview
  76. 12.13.3 Medisol Lifescience Pvt. Ltd. Revenue in Pulmonary Drugs Business (2021-2026)
  77. 12.13.4 Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Product Portfolio
  78. 12.13.5 Medisol Lifescience Pvt. Ltd. Recent Developments
  79. 12.14 Meda Pharmaceuticals
  80. 12.14.1 Meda Pharmaceuticals Company Information
  81. 12.14.2 Meda Pharmaceuticals Business Overview
  82. 12.14.3 Meda Pharmaceuticals Revenue in Pulmonary Drugs Business (2021-2026)
  83. 12.14.4 Meda Pharmaceuticals Pulmonary Drugs Product Portfolio
  84. 12.14.5 Meda Pharmaceuticals Recent Developments
  85. 12.15 Mallinckrodt Pharmaceuticals Plc.
  86. 12.15.1 Mallinckrodt Pharmaceuticals Plc. Company Information
  87. 12.15.2 Mallinckrodt Pharmaceuticals Plc. Business Overview
  88. 12.15.3 Mallinckrodt Pharmaceuticals Plc. Revenue in Pulmonary Drugs Business (2021-2026)
  89. 12.15.4 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio
  90. 12.15.5 Mallinckrodt Pharmaceuticals Plc. Recent Developments
  91. 12.16 Lupin Ltd.
  92. 12.16.1 Lupin Ltd. Company Information
  93. 12.16.2 Lupin Ltd. Business Overview
  94. 12.16.3 Lupin Ltd. Revenue in Pulmonary Drugs Business (2021-2026)
  95. 12.16.4 Lupin Ltd. Pulmonary Drugs Product Portfolio
  96. 12.16.5 Lupin Ltd. Recent Developments
  97. 12.17 Grifols, S.A.
  98. 12.17.1 Grifols, S.A. Company Information
  99. 12.17.2 Grifols, S.A. Business Overview
  100. 12.17.3 Grifols, S.A. Revenue in Pulmonary Drugs Business (2021-2026)
  101. 12.17.4 Grifols, S.A. Pulmonary Drugs Product Portfolio
  102. 12.17.5 Grifols, S.A. Recent Developments
  103. 12.18 F. Hoffmann La Roche Ltd.
  104. 12.18.1 F. Hoffmann La Roche Ltd. Company Information
  105. 12.18.2 F. Hoffmann La Roche Ltd. Business Overview
  106. 12.18.3 F. Hoffmann La Roche Ltd. Revenue in Pulmonary Drugs Business (2021-2026)
  107. 12.18.4 F. Hoffmann La Roche Ltd. Pulmonary Drugs Product Portfolio
  108. 12.18.5 F. Hoffmann La Roche Ltd. Recent Developments
  109. 12.19 Circassia Pharmaceuticals Plc.
  110. 12.19.1 Circassia Pharmaceuticals Plc. Company Information
  111. 12.19.2 Circassia Pharmaceuticals Plc. Business Overview
  112. 12.19.3 Circassia Pharmaceuticals Plc. Revenue in Pulmonary Drugs Business (2021-2026)
  113. 12.19.4 Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio
  114. 12.19.5 Circassia Pharmaceuticals Plc. Recent Developments
  115. 12.20 Cipla Ltd.
  116. 12.20.1 Cipla Ltd. Company Information
  117. 12.20.2 Cipla Ltd. Business Overview
  118. 12.20.3 Cipla Ltd. Revenue in Pulmonary Drugs Business (2021-2026)
  119. 12.20.4 Cipla Ltd. Pulmonary Drugs Product Portfolio
  120. 12.20.5 Cipla Ltd. Recent Developments
  121. 12.21 Cheisi Farmaceutici S.p.A
  122. 12.21.1 Cheisi Farmaceutici S.p.A Company Information
  123. 12.21.2 Cheisi Farmaceutici S.p.A Business Overview
  124. 12.21.3 Cheisi Farmaceutici S.p.A Revenue in Pulmonary Drugs Business (2021-2026)
  125. 12.21.4 Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Portfolio
  126. 12.21.5 Cheisi Farmaceutici S.p.A Recent Developments
  127. 12.22 Celon Pharma SA
  128. 12.22.1 Celon Pharma SA Company Information
  129. 12.22.2 Celon Pharma SA Business Overview
  130. 12.22.3 Celon Pharma SA Revenue in Pulmonary Drugs Business (2021-2026)
  131. 12.22.4 Celon Pharma SA Pulmonary Drugs Product Portfolio
  132. 12.22.5 Celon Pharma SA Recent Developments
  133. 12.23 Boehringer Ingelheim
  134. 12.23.1 Boehringer Ingelheim Company Information
  135. 12.23.2 Boehringer Ingelheim Business Overview
  136. 12.23.3 Boehringer Ingelheim Revenue in Pulmonary Drugs Business (2021-2026)
  137. 12.23.4 Boehringer Ingelheim Pulmonary Drugs Product Portfolio
  138. 12.23.5 Boehringer Ingelheim Recent Developments
  139. 12.24 Aurobindo Pharma Ltd.
  140. 12.24.1 Aurobindo Pharma Ltd. Company Information
  141. 12.24.2 Aurobindo Pharma Ltd. Business Overview
  142. 12.24.3 Aurobindo Pharma Ltd. Revenue in Pulmonary Drugs Business (2021-2026)
  143. 12.24.4 Aurobindo Pharma Ltd. Pulmonary Drugs Product Portfolio
  144. 12.24.5 Aurobindo Pharma Ltd. Recent Developments
  145. 12.25 Alaxia SAS
  146. 12.25.1 Alaxia SAS Company Information
  147. 12.25.2 Alaxia SAS Business Overview
  148. 12.25.3 Alaxia SAS Revenue in Pulmonary Drugs Business (2021-2026)
  149. 12.25.4 Alaxia SAS Pulmonary Drugs Product Portfolio
  150. 12.25.5 Alaxia SAS Recent Developments
  151. 12.26 Aerogen Pharma Ltd.
  152. 12.26.1 Aerogen Pharma Ltd. Company Information
  153. 12.26.2 Aerogen Pharma Ltd. Business Overview
  154. 12.26.3 Aerogen Pharma Ltd. Revenue in Pulmonary Drugs Business (2021-2026)
  155. 12.26.4 Aerogen Pharma Ltd. Pulmonary Drugs Product Portfolio
  156. 12.26.5 Aerogen Pharma Ltd. Recent Developments
  157. 12.27 Abbott Laboratories
  158. 12.27.1 Abbott Laboratories Company Information
  159. 12.27.2 Abbott Laboratories Business Overview
  160. 12.27.3 Abbott Laboratories Revenue in Pulmonary Drugs Business (2021-2026)
  161. 12.27.4 Abbott Laboratories Pulmonary Drugs Product Portfolio
  162. 12.27.5 Abbott Laboratories Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst